 |
|
|
| |
Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) in Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil
|
| |
| |
EASL
Reported by Jules Levin
T Berg,1 B Moller,1 H Trinh,2 S Chan,3 P Marcellin,4 E Suarez,5 A Snow-Lampart,6 D Oldach,6 J Sorbel,6 K Borroto-Esoda,6 D Frederick,6 and F Rousseau6
1Berlin, Germany; 2San Jose, CA, USA; 3Flushing, NY, USA; 4Clichy, France; 5Sevilla, Spain; 6Gilead Sciences, Inc., Durham, NC, USA
AUTHOR CONCLUSIONS
Both treatment strategies (TDF monotherapy with option to add FTC as combination FTC/TDF, or initial combination of FTC/TDF) were equivalent through 96 weeks of follow-up in this heavily pretreated, highly viremic population
There is a non significant trend favoring combination for antiviral efficacy when considering subjects who added FTC or switched from blinded FTC/TDF to open-label as failures
In patients with incomplete viral suppression on ADV majority with prior/current LAM use, the complete viral suppression noted in most patients at Week 48 on TDF or FTC/TDF (81% in both arms) was maintained at Week 96 (89% TDF; 85% FTC/TDF)
Virologic response was independent of pre-existing ADV or LAM-associated mutations
Reference
1. Berg et al, EASL 2008;
|
| |
|
|
|
|
|
